En Carta Diagnostics announced a €5 million first closing on July 10. By then the Paris company had already signed a €13 million commercial agreement that commits it to delivering several million test units over five years. Buyer first, capacity second. Most hardware founders run that order backwards and then wonder why the scale-up hurts.
The €5 million splits into €3 million of equity led by Blue Forest Ventures, with Ring Capital, CentraleSupélec Venture, 50 Partners Health and a group of angels alongside, plus €2 million in non-dilutive financing from Bpifrance and other partners. It follows a €1.5 million pre-seed in 2024. On its own that is an ordinary European seed story.
Guillaume Horreard and Margot Karlikow founded En Carta in 2022 to put PCR-grade molecular testing into a single-use cassette a patient can run without a lab, with a result in about thirty minutes. The platform uses aptamers, which bind to a programmed target sequence, so the same cassette architecture can be pointed at different pathogens. The first indication is early Lyme detection. The second is chlamydia and gonorrhoea screening.
The commercial commitment is larger than the round
That second indication is where the AAZ agreement sits. AAZ is a French company that sells self-tests and rapid diagnostics. EU-Startups reported the co-development and commercialisation deal as a €13 million commercial partnership with committed volumes of several million units across five years in Europe. En Carta also went fabless on the hardware, partnering with Circum Medical to manufacture at volume rather than standing up its own line.
An equity round tells you a handful of investors believe the thesis. A volume commitment from a company that already owns shelf space and distributor relationships tells you someone has put their own forecast behind your product. Those are different grades of evidence, and only one of them survives a bad quarter.
I have watched too many hard-tech teams fall in love with the engineering instead of the customer. A working demo feels like progress, and it is not progress if nobody has proven they will pay at a margin that lets the company live. Build the customer proof before you build the fleet. En Carta did that in the right order, and the fabless decision means this capital goes into regulatory work and launch rather than into a factory nobody has ordered from yet.
A Breakthrough Designation buys access, not permission
In January 2026 the FDA granted Breakthrough Device Designation to EC Pocket Lyme, En Carta’s test for detecting Borrelia directly from skin interstitial fluid at a tick bite. The designation gives the company priority review and interactive communication with FDA reviewers and senior leadership. It does not authorize a single sale. Founders and their investors routinely read it as though it does.
At Galen we learned how thin an FDA yes can be. Our Q-sub said we would run a sixteen-subject cadaver study using residents, and the agency wrote back and told us to go for it. Months later, in substantive review, the first question was whether we intended to market to residents. The study design they had approved in writing was suddenly the problem. I went to Johns Hopkins with my hat in my hand, got a free OR and cadaver heads, and re-ran the entire study with sixteen attending surgeons in two weeks.
What that taught me is that a written agency response is one reviewer’s read on one day, and that your test population is itself a claim about who you intend to sell to. En Carta is running clinical trials in Boston and in Białystok, Poland, which is the right instinct. Build the evidence inside the markets you actually intend to enter, and build it as though the conversation is going to get harder rather than easier.
The number I would want on the wall at En Carta is the AAZ volume commitment, not the FDA letter. The letter opens a door at the agency. The volume commitment is a company with a sales force saying it will move millions of units, and that is the only evidence telling you the product has somewhere to go once the door opens. If you are building a diagnostic, or any regulated hardware, get the committed order before you get the press release.
From Dave’s video library
Dave walks through what a fractional CPO engagement actually costs, what the work looks like week to week, and why six months is the floor before it produces anything real.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour working session →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for hard-tech founders. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →